Qiagen N.V. Share Price

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse 21:00:02 19/07/2024 BST 5-day change 1st Jan Change
41.55 USD -0.55% Intraday chart for Qiagen N.V. -1.49% -7.20%
Sales 2024 * 2B 155B Sales 2025 * 2.12B 165B Capitalization 9.22B 714B
Net income 2024 * 402M 31.14B Net income 2025 * 444M 34.39B EV / Sales 2024 * 4.71 x
Net Debt 2024 * 196M 15.22B Net cash position 2025 * 226M 17.49B EV / Sales 2025 * 4.23 x
P/E ratio 2024 *
22.9 x
P/E ratio 2025 *
20.3 x
Employees 5,900
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.86%
More Fundamentals * Estimated data
Dynamic Chart
1 day-0.55%
1 week-1.49%
Current month+1.12%
1 month-0.81%
3 months+3.88%
6 months-10.69%
Current year-7.20%
More quotes
1 week
40.91
Extreme 40.91
42.79
1 month
39.73
Extreme 39.73
42.79
Current year
39.03
Extreme 39.03
47.29
1 year
35.81
Extreme 35.8144
49.18
3 years
35.81
Extreme 35.8144
59.79
5 years
25.81
Extreme 25.8144
60.82
10 years
21.35
Extreme 21.3474
60.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 31/01/15
Founder 69 28/04/96
Director of Finance/CFO 56 31/12/98
Members of the board TitleAgeSince
Director/Board Member 74 31/05/11
Founder 69 28/04/96
Chairman 66 25/06/13
More insiders
Date Price Change Volume
19/07/24 41.55 -0.55% 1,092,398
18/07/24 41.78 -1.65% 1,044,316
17/07/24 42.48 -0.21% 1,380,767
16/07/24 42.57 +1.84% 1,009,011
15/07/24 41.8 -0.90% 1,914,445

Delayed Quote Nyse, July 19, 2024 at 09:00 pm

More quotes
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
41.55 USD
Average target price
49.92 USD
Spread / Average Target
+20.14%
Consensus